Tourmaline Bio Operating Expenses 2020-2025 | TRML

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Tourmaline Bio operating expenses from 2020 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Tourmaline Bio operating expenses from 2020 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$80.8B
Zoetis (ZTS)	$65.6B
Daiichi Sankyo, - (DSNKY)	$46.7B
Takeda Pharmaceutical (TAK)	$45.1B
BeOne Medicines - (ONC)	$32.8B
Sandoz Group AG (SDZNY)	$25.1B
Summit Therapeutics (SMMT)	$20.1B
Merck (MKKGY)	$16.1B
Shionogi (SGIOY)	$14.5B
United Therapeutics (UTHR)	$13.3B
Neurocrine Biosciences (NBIX)	$12.8B
Orion OYJ (ORINY)	$11.5B
IPSEN (IPSEY)	$10.8B
Stevanato Group S.p.A (STVN)	$7.6B
Grifols, S.A (GRFS)	$7.4B
Corcept Therapeutics (CORT)	$7.3B
Ionis Pharmaceuticals (IONS)	$6.9B
Madrigal Pharmaceuticals (MDGL)	$6.7B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.3B
Hypermarcas (HYPMY)	$2.9B
Crinetics Pharmaceuticals (CRNX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
NewAmsterdam Pharma (NAMS)	$2.4B
Centessa Pharmaceuticals (CNTA)	$2.2B
Ocular Therapeutix (OCUL)	$1.9B
Endo (NDOI)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.7B